Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
Abstract
The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 21, 2021
- Source ID
- 10.1101/2021.12.10.21267485
Entities
People
- Aaron A.r. Tobian
- Aarthi Shenoy
- Adam C. Levine
- Amy L. Gawad
- Andrew Pekosz
- Anusha Yarava
- Arturo Casadevall
- Atika Singh
- Barry R. Meisenberg
- Bela Patel
- Benjamin Greenblatt
- Bryan Lau
- Catherine G. Sutcliffe
- Christi E. Marshall
- Daniel Cruser
- Daniel E. Ford
- Daniel F Hanley
- David M. Shade
- David Sullivan
- Donald N. Forthal
- Douglas A. Jabs
- E. Colin Foster
- Edward R. Cachay
- Emily S. Spivak
- Evan M Bloch
- Giselle Mosnaim
- James H. Paxton
- Janis E. Blair
- Jay S Raval
- Jean Hammel
- Joann R. Petrini
- Jonathan M. Gerber
- Judith S. Currier
- Karen Lane
- Kelly A. Gebo
- Kevin Oei
- Laura L. Hammitt
- Lawrence J. Appel
- Marie Elena Cordisco
- Martin S Zand
- Matthew Abinante
- Michael E Roth
- Moises A. Huamán
- Nichol A. Mcbee
- Nicky Karlen
- Oliver Laeyendecker
- Patrick B. Broderick
- Sabra Klein
- Seble G. Kassaye
- Sheriza N. Baksh
- Shmuel Shoham
- Shweta Anjan
- Sonya L Heath
- Stephan Ehrhardt
- Thomas J. Gniadek
- Valerie C. Cluzet
- William Rausch
- Yuriko Fukuta